We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by Newark Beth Israel Medical Center.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01170338
First Posted: July 27, 2010
Last Update Posted: July 27, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Newark Beth Israel Medical Center
  Purpose
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Condition Intervention Phase
Smoking Acute Coronary Syndrome Drug: Varenicline 100 mg by mouth twice daily Drug: control Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Resource links provided by NLM:


Further study details as provided by Newark Beth Israel Medical Center:

Primary Outcome Measures:
  • nicotine levels [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • recurrent myocardial ischemia [ Time Frame: 1 month ]

Estimated Enrollment: 100
Study Start Date: January 2008
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: active Chantix
active drug to help smoking cessation
Drug: Varenicline 100 mg by mouth twice daily
this is an active drug to help smoking cessation
Placebo Comparator: sugar pill Drug: control
this is the placebo that will help us maintain a blinded study

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • active smokers presenting to hospital with an acute coronary syndrome

Exclusion Criteria:

  • patients with an acute coronary syndrome who are not active smokers
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01170338


Locations
United States, New Jersey
Newark Beth Israel Medical Center Recruiting
Newark, New Jersey, United States, 07112
Contact: Marc Cohen, MD    973-926-7852    marcohen@sbhcs.com   
Principal Investigator: Marc Cohen, MD         
Sponsors and Collaborators
Newark Beth Israel Medical Center
  More Information

Responsible Party: Marc Cohen, MD, Newark Beth Israel Medical Ctr
ClinicalTrials.gov Identifier: NCT01170338     History of Changes
Other Study ID Numbers: 2008.68
First Submitted: July 26, 2010
First Posted: July 27, 2010
Last Update Posted: July 27, 2010
Last Verified: July 2010

Keywords provided by Newark Beth Israel Medical Center:
smoking
tobacco abuse

Additional relevant MeSH terms:
Syndrome
Acute Coronary Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Varenicline
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs